NEW YORK, April 20 (Reuters) - Pfizer Inc. said on Friday it was placing a hold on development of any drugs in the same class as torcetrapib, its experimental product that dramatically raised "good" HDL cholesterol but was scrapped after being linked to deaths in a large trial.
